4D Molecular Therapeutics (FDMT) Revenue & Revenue Breakdown
4D Molecular Therapeutics Revenue Highlights
Main Segment (Y)
Collaboration And License Revenue
Main Geography (Y)
UNITED STATES
4D Molecular Therapeutics Revenue by Period
4D Molecular Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $3.13M | -82.65% |
| 2021-12-31 | $18.04M | 32.52% |
| 2020-12-31 | $13.61M | 94.85% |
| 2019-12-31 | $6.99M | -50.56% |
| 2018-12-31 | $14.13M | 144.04% |
| 2017-12-31 | $5.79M | - |
4D Molecular Therapeutics generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
4D Molecular Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $28.00K | -247.37% |
| 2023-12-31 | $-19.00K | -100.09% |
| 2023-09-30 | $20.20M | 8353.56% |
| 2023-06-30 | $239.00K | -19.80% |
| 2023-03-31 | $298.00K | -76.10% |
| 2022-12-31 | $1.25M | 149.40% |
| 2022-09-30 | $500.00K | 208.64% |
| 2022-06-30 | $162.00K | -86.71% |
| 2022-03-31 | $1.22M | 1225.00% |
| 2021-12-31 | $92.00K | -93.27% |
| 2021-09-30 | $1.37M | -90.63% |
| 2021-06-30 | $14.58M | 629.00% |
| 2021-03-31 | $2.00M | -304.71% |
| 2020-12-31 | $-977.00K | -113.17% |
| 2020-09-30 | $7.42M | 104.27% |
| 2020-06-30 | $3.63M | 2.77% |
| 2020-03-31 | $3.54M | 74.14% |
| 2019-12-31 | $2.03M | 275.93% |
| 2019-09-30 | $540.00K | -75.54% |
| 2019-06-30 | $2.21M | - |
| 2019-03-31 | $2.21M | -51.26% |
| 2018-12-31 | $4.53M | - |
| 2018-09-30 | $4.53M | 78.75% |
| 2018-06-30 | $2.53M | - |
| 2018-03-31 | $2.53M | - |
4D Molecular Therapeutics generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
4D Molecular Therapeutics Revenue Breakdown
4D Molecular Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Collaboration And License Revenue | $20.01M | $3.13M | $18.04M | $13.61M |
4D Molecular Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration And License Revenue (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration And License Revenue | $28.00K | - | $20.01M | $239.00K | $298.00K | $1.25M | $500.00K | $162.00K | $1.22M | $12.00K | $64.00K | $14.58M | $2.00M |
4D Molecular Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Collaboration And License Revenue (100.00%).
4D Molecular Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| NETHERLANDS | $567.00K | $3.09M | $736.00K | $742.00K |
| UNITED STATES | $20.16M | $35.00K | $121.00K | $-27.00K |
| SWITZERLAND | - | - | $17.18M | $12.90M |
| AUSTRALIA | - | - | - | - |
4D Molecular Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (97.26%), and NETHERLANDS (2.74%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $28.00K | - | $20.16M | $9.00K | $3.00K | $2.00K | $3.00K | $2.00K | $28.00K | $89.00K | $12.00K | $16.00K | $3.00K |
| NETHERLANDS | - | $1.00K | $41.00K | $230.00K | $295.00K | $1.25M | $497.00K | $160.00K | $1.19M | $12.00K | $64.00K | $267.00K | $392.00K |
| SWITZERLAND | - | - | - | - | - | - | - | - | - | $-9.00K | $1.29M | $14.30M | $1.60M |
4D Molecular Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (100.00%).
4D Molecular Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| KRON | Kronos Bio | $6.29M | $2.69M |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| FIXX | Q32 Bio | $1.16M | - |
| BCEL | Atreca | $770.00K | $80.00K |
| CGEM | Cullinan Oncology | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| CCCC | C4 Therapeutics | - | - |
| GOSS | Gossamer Bio | - | $95.84M |
| REPL | Replimune Group | - | - |
| PASG | Passage Bio | - | - |
| BMEA | Biomea Fusion | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| NVCT | Nuvectis Pharma | - | - |
| AKRO | Akero Therapeutics | - | - |
| FDMT | 4D Molecular Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
FDMT Revenue FAQ
What is 4D Molecular Therapeutics’s yearly revenue?
4D Molecular Therapeutics's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $3.13M, representing a decrease of -82.65% compared to 2021. FDMT's yearly revenue for 2021 was $18.04M, representing an increase of 32.52% compared to 2020.
What is 4D Molecular Therapeutics’s quarterly revenue?
4D Molecular Therapeutics's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $28K, a -247.37% decrease from the previous quarter (Q4 2023), and a -90.60% decrease year-over-year (Q1 2023). FDMT's quarterly revenue for Q4 2023 was $-19K, a -100.09% decrease from the previous quarter (Q3 2023), and a -101.52% decrease year-over-year (Q4 2022).
What is 4D Molecular Therapeutics’s revenue growth rate?
4D Molecular Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.
What are 4D Molecular Therapeutics’s revenue streams?
4D Molecular Therapeutics's revenue streams in c 23 are Collaboration And License Revenue
What is 4D Molecular Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of 4D Molecular Therapeutics was Collaboration And License Revenue. This segment made a revenue of $20.01M, representing 100.00% of the company's total revenue.